close
close

Aminoglycosides market poised to reach $2.9 billion by 2033

The aminoglycosides market is poised for significant expansion, with forecasts indicating the market will grow from $1.8 billion in 2023 to approximately $2.9 billion in 2033, reflecting a compound annual growth rate (CAGR) of 4.8% over the forecast period of 2024 through 2033. 2033. This growth is primarily driven by the increasing prevalence of bacterial infections, especially in healthcare settings, which necessitates the use of effective antibiotics such as aminoglycosides. Furthermore, the global increase in surgical procedures has increased the demand for these antibiotics to prevent postoperative infections.

Recent developments in the market include the approval of new drug formulations and innovative treatments. For example, in March 2022, Padagis received FDA approval for a generic version of Tobradex Ophthalmic Suspension, which combines tobramycin and dexamethasone for the treatment of steroid-responsive inflammatory eye diseases. In addition, ongoing research is aimed at improving the efficacy of aminoglycosides and developing combination therapies to improve treatment outcomes.

However, the market faces significant challenges due to the adverse side effects associated with aminoglycosides, such as ototoxicity and nephrotoxicity, which may limit their use. Moreover, the lengthy approval processes for new drugs and the stringent regulatory environment can hinder market growth.

Despite these challenges, the market offers plenty of opportunities, especially in emerging economies in the Asia-Pacific region, where healthcare needs and economic development are driving demand. The adaptability of the market and continuous innovations in drug formulations underline the potential for sustainable growth.

Key learning points

  • The aminoglycosides market is expected to grow with a turnover of 4.8% CAGR, range $2.9 billion by 2033 from $1.8 billion in 2023.
  • Gentamicin leads the market with a 32.5% share, highlighting its popularity among consumers and professionals due to its effectiveness.
  • Parenteral administration involves a 30.8% market share, which is preferable due to quick action in treating serious infections.
  • The Respiratory Diseases segment leads with a 41.6% market share, due to the increasing prevalence of respiratory diseases.
  • Asia Pacific dominates the market with a 41.5% share, driven by healthcare needs, population growth and economic development.
  • The worldwide increase in bacterial infections drives the demand for aminoglycosides.
  • Emerging markets, especially in APAC, offer significant growth opportunities for the aminoglycosides market.
  • Ongoing research into new compounds and personalized medicine offers new growth opportunities for the market.
  • Safety concerns, such as ototoxicity and nephrotoxicity, limit the use of aminoglycosides.
  • The trend to combine aminoglycosides with other antibiotics is growing for better treatment results.

Get a sample PDF report: https://market.us/report/aminoglycosides-market/request-sample/

Aminoglycosides Market Key Segments

Product

  • Neomycin
  • Tobramycin
  • Gentamicin
  • Amikacin
  • Paromomycin
  • Streptomycin
  • Kanamycin
  • Others

Administrative route

  • Parenteral
  • Intra-mammary
  • Topical
  • Oral

Application

  • Veterinary
  • Skin infection
  • Respiratory diseases
  • UTI and pelvic diseases
  • Other diseases

Main regions

  • North America (USA, Canada, Mexico)
  • Western Europe (Germany, France, Great Britain, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Scandinavia, rest of Western Europe)
  • Eastern Europe (Russia, Poland, Czech Republic, Greece, rest of Eastern Europe)
  • APAC (China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, rest of APAC)
  • Latin America (Brazil, Colombia, Chile, Argentina, Costa Rica, rest of Latin America)
  • Middle East and Africa (Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, UAE, rest of MEA)

Buy directly: https://market.us/purchase-report/?report_id=25197

Analysis of the key players

Vega Pharma Ltd. is a major player in the aminoglycosides market and is known for its robust research and development initiatives. The company focuses on innovating and producing high-quality aminoglycoside antibiotics to meet the needs of healthcare providers and patients worldwide. Vega Pharma’s commitment to pharmaceutical excellence and its continuous efforts in developing new products ensure that Vega Pharma is a prominent contributor to the market.

Kremoint Pharma is known for its strict quality control and compliance with regulatory standards in the production of aminoglycosides. The company prioritizes the production of high-quality antibiotics, ensuring the reliability and effectiveness of its products. This commitment to quality has made Kremoint Pharma a trusted name in the aminoglycosides sector.

Xian Wison Biological Technology integrates advanced biological technologies with pharmaceutical innovations. This company is known for its sustainable practices and commitment to environmentally friendly solutions. Their innovative approach and focus on environmentally friendly processes contribute significantly to their position in the aminoglycosides market.

Jiangxi Bolai Pharmacy offers a wide range of pharmaceutical products including aminoglycosides. The company’s strategic market expansion and continued investments in research and development have strengthened its competitive position. Jiangxi Bolai Pharmacy’s broad product portfolio and strategic initiatives make it a major player in the industry.

Medson Pharmaceuticals is actively involved in the aminoglycosides market and uses its expertise to produce effective antibiotics. The company’s focus on innovation and quality assurance ensures that it remains competitive in the marketplace. Medson Pharmaceuticals’ commitment to meeting healthcare needs positions the company as a key market participant.

Hangzhou Uniwise International operates with a focus on international standards and market needs. The company emphasizes on the production of high-quality aminoglycosides and other pharmaceutical products, targeting both the domestic and global markets. Their commitment to quality and compliance with international regulations underlines their role in the aminoglycosides sector.

Key Players in the Aminoglycosides Market:

  • Vega Pharma
  • Kremount Pharma
  • Xian Wison Biological Technology Co.
  • Jiangxi Bolai Pharmacy Co.
  • Medson pharmaceutical products
  • Hangzhou Uniwise International Co.

Aminoglycosides Market Report Scope >> Market value (2023): USD 1.8 billion || Projected revenue (2033): $2.9 billion || CAGR (2024-2033): 4.8% || Base year estimate: 2023 || Historical period: 2019-2022 || Forecast period: 2024-2033.

Inquire More about report: https://market.us/report/aminoglycosides-market/#inquiry

About Market.US

Market.US is known for its extensive market research and analysis, providing customized and syndicated reports to a global client base. They specialize in different sectors and provide strategic insights and detailed market forecasts, helping companies make informed decisions. With a focus on innovation and accuracy, Market.US serves customers in more than 126 countries and maintains a strong repeat customer base, underscoring their commitment to quality and customer satisfaction. Their team excels in providing exceptional research services and ensures that no detail is overlooked in any target market.

Contact details
Market.us (Powered by Prudour Pvt. Ltd.)
Contact number: +1 718 618 4351.
Email: [email protected]
Blog: https://medicalmarketreport.com/

View more trend reports

The growth of the digital PCR market is expected to reach USD 1,803 million by 2033, with an estimated CAGR of 15.3%

The sterilization equipment market will grow by nearly $32.4 billion at a rate of 9.4% by 2032

Market valuation of platelet-rich plasma expected to reach $342 million by 2033, demonstrating a CAGR of 10.5%

The ophthalmic devices market will reach $76 billion by 2033 and achieve a CAGR of approximately 4.8%

eClinical Solutions Market Outlook: Expected to Expand to $27 Billion, Maintaining a CAGR of 12.8%